Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00019422 · ClinicalTrials.gov registry record · Phase 2

Lobradimil and Carboplatin in Treating Children With Brain Tumors

A Phase 2 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase

NCT00019422: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).

NCT00019422 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00019422, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Lobradimil may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of carboplatin and lobradimil in treating children with brain tumors that have not responded to previous treatment.

Interventions

  • DRUG carboplatin
  • DRUG lobradimil

Trial Details

FieldValue
Start Date 1998-03
Est. Completion 2003-04
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00019422

The ClinicalTrials.gov registry entry for NCT00019422 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which carboplatin is the first listed.

NCT00019422 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00019422 about?

NCT00019422 is a clinical study titled "Lobradimil and Carboplatin in Treating Children With Brain Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Lobradimil may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of carboplati...

What is the current status of trial NCT00019422?

This trial is currently completed. It is a Phase 2 study. The study started on 1998-03. Estimated completion is 2003-04.

What interventions are being tested in trial NCT00019422?

The interventions under investigation include: carboplatin (DRUG), lobradimil (DRUG).

Who is sponsoring clinical trial NCT00019422?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.